EKSO EKSO BIONICS HOLDINGS, INC. Insider Trading

CFO Wong Jerome bought 1,308 shares ($15.5K) of EKSO at $11.85; stock now down -18.6%, company unprofitable with -28.6% annual revenue decline

Jerome Wong, CFO of EKSO Bionics, purchased 1,308 shares at $11.85 on 2026-03-16, increasing his holdings by 45.5% to 4,184 shares total. The purchase occurred at a price that is now $1.31 above the current market price of $10.54, representing an unrealized loss on the transaction. The timing of the buy is notable given that the company is unprofitable with net income of $-1,421,000.00 in the latest quarter and has experienced -28.6% annual revenue decline, while the stock has dropped -18.6% in the 30 days since the transaction. The CFO's substantial increase in personal share position despite deteriorating fundamentals and negative recent price momentum warrants investor scrutiny of the underlying business trajectory and whether this reflects confidence in a turnaround or other considerations.

EKSO COO Jason C Jones bought 1,308 shares at $11.85 on 2026-03-16; stock down 18.6% since

Jason C Jones, Chief Operating Officer of Ekso Bionics Holdings, purchased 1,308 shares at $11.85 on 2026-03-16, increasing his holdings by 41.6% from 3,141 to 4,449 shares. The transaction occurred near the 52-week high (current price $10.54 is -18.6% from the $12.95 peak) and the company faces significant operational headwinds: revenue declined 28.6% year-over-year to $4.2M in the latest quarter, with the company unprofitable (net income of $-1.4M) and a market cap of only $37.6M. The COO's purchase of $15.5K in stock does occur in a market recovery context (90-day change: +116.9%), but this modest accumulation by a single executive in a micro-cap biomedical device company with deteriorating revenue and persistent losses provides limited inference about company-level confidence without broader insider participation or strategic commentary.

10% owner Asher Daniel purchased 15,540 shares of EKSO at $12.30 on 2026-02-19; fourth buy in one week as stock up 42.4% in 30 days from $2.82–$12.95 range.

Asher Daniel, a 10% owner, executed his fourth purchase of EKSO in one week (prior buys on 2026-02-12 and 2026-02-13), acquiring 15,540 shares at $12.30 for $191,162.20. The timing coincides with sharp recent momentum: the stock has risen 42.4% over 30 days and 174.0% over 90 days, now trading at $11.18, down 13.7% from the 52-week high of $12.95. This represents a 6.1% increase in his holdings to 270,432 shares. However, the company remains unprofitable with a net income of $-1,421,000.00 in the latest quarter and -1.9% annual revenue growth, limiting confidence signals from fundamentals. The rapid sequence of open-market purchases during a volatile rally period warrants tracking the sustainability of his ownership accumulation against baseline profitability metrics.

10% Owner Asher Daniel buys 1,200 shares of EKSO at $9.60; stock up 49.6% in 30 days but company remains unprofitable.

Asher Daniel, a 10% owner of Ekso Bionics, purchased 1,200 shares at $9.60 on 2026-02-19, bringing his holdings to 259,992 shares. This represents the fifth buy transaction by this insider in six days (also purchasing on 2026-02-12 and 2026-02-13), suggesting accumulated accumulation activity during a period of strong price momentum. The stock has gained 49.6% over the past 30 days and 201.5% over 90 days, trading at $12.30 versus a 52-week high of $12.95. However, this price strength contrasts sharply with weak fundamentals: the company reported negative net income of $-1.4M in its latest quarter against revenue of only $4.2M, remains unprofitable on a full-year basis, and shows negative annual revenue growth of -1.9%. The insider's cross-ticker buy history shows an average 30-day return of -4.6%, and his prior EKSO trades are too recent to have measurable outcomes. The recent accumulation by a major shareholder during a period of elevated valuation against deteriorating earnings warrants monitoring of whether this activity reflects confidence in a turnaround or occurs amid a fundamental disconnect.

10% owner ASHER DANIEL bought 102,029 shares totaling $970,069.48 in 8 transactions over 8 days at avg $9.51

ASHER DANIEL, a 10% owner of EKSO BIONICS HOLDINGS, INC., executed 8 separate purchases totaling 102,029 shares for $970,069.48 between 2026-02-06 and 2026-02-13, raising his holdings from 156,763 shares to 258,792 shares (+65.1%). The blended average price across these transactions was $9.51, while the stock now trades at $11.16 (currently at its 52-week high). The purchases occurred amid strong recent price momentum: the stock has rallied +26.0% over 30 days and +176.9% over 90 days from a 52-week low of $2.82. However, context demands caution: the company posted negative net income of $-1,421,000.00 in the latest quarter, remains unprofitable on a full-year basis, and has experienced -1.9% annual revenue growth. EKSO's market cap stands at only $29,275,280.28. The 10% owner's cross-ticker track record shows an average 30-day return of -4.8% on his 10 prior open-market purchases, suggesting limited predictive power from his historical buying decisions.